MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Axsome Therapeutics Inc

Закрыт

СекторЗдравоохранение

107.41 -2.09

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

107.33

Макс.

109.38

Ключевые показатели

By Trading Economics

Доход

-10M

-75M

Продажи

14M

119M

Прибыль на акцию

-1.54

Рентабельность продаж

-63.075

Сотрудники

683

EBITDA

-10M

-71M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+58.81% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

5 мая 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-458M

5.8B

Предыдущая цена открытия

109.5

Предыдущая цена закрытия

107.41

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Axsome Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 апр. 2025 г., 23:04 UTC

Главные новости

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 апр. 2025 г., 22:40 UTC

Главные движущие силы рынка

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 апр. 2025 г., 22:18 UTC

Приобретения, слияния, поглощения

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 апр. 2025 г., 18:51 UTC

Приобретения, слияния, поглощения

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 апр. 2025 г., 23:43 UTC

Обсуждения рынка

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 апр. 2025 г., 23:41 UTC

Обсуждения рынка

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 апр. 2025 г., 22:22 UTC

Приобретения, слияния, поглощения

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 апр. 2025 г., 22:21 UTC

Приобретения, слияния, поглощения

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 апр. 2025 г., 21:43 UTC

Главные новости
Отчет

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 апр. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

3 апр. 2025 г., 20:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

3 апр. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

3 апр. 2025 г., 20:43 UTC

Обсуждения рынка

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 апр. 2025 г., 20:34 UTC

Главные новости

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 апр. 2025 г., 20:23 UTC

Главные новости

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 апр. 2025 г., 20:15 UTC

Приобретения, слияния, поглощения

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 апр. 2025 г., 19:55 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

3 апр. 2025 г., 19:55 UTC

Обсуждения рынка

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 апр. 2025 г., 19:21 UTC

Обсуждения рынка

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 апр. 2025 г., 19:15 UTC

Обсуждения рынка

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 апр. 2025 г., 18:45 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

3 апр. 2025 г., 18:45 UTC

Обсуждения рынка

Gold Drops In Tariff Fallout -- Market Talk

3 апр. 2025 г., 18:39 UTC

Обсуждения рынка

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 апр. 2025 г., 18:38 UTC

Главные новости

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 апр. 2025 г., 18:30 UTC

Главные новости

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 апр. 2025 г., 18:20 UTC

Обсуждения рынка

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 апр. 2025 г., 18:18 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

3 апр. 2025 г., 18:17 UTC

Обсуждения рынка

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 апр. 2025 г., 18:04 UTC

Обсуждения рынка

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 апр. 2025 г., 17:55 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

Axsome Therapeutics Inc Прогноз

Целевая цена

By TipRanks

58.81% рост

Прогноз на 12 месяцев

Средняя 174.29 USD  58.81%

Максимум 216 USD

Минимум 133 USD

Основано на мнении 17 аналитиков Wall Street, спрогнозировавших целевые цены для Axsome Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

17 ratings

17

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

107 / 113.5Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Neutral Evidence

Долгосрочная

Strong Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.